Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.44 |
| ▸ | MET | P08581 | 6/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734269 | 1.00 | HRH3 (0.54) | HRH3BRAFEGLN1METEPHX2 | |
| Hydrochloric Acid SCHEMBL2743505 | 0.99 | HRH3 (0.53) | HRH3BRAFEGLN1METEPHX2 | |
| Hydrochloric Acid SCHEMBL2743503 | 0.99 | HRH3 (0.53) | HRH3BRAFEGLN1METEPHX2 | |
| SCHEMBL1793748 | 0.85 | HRH3 (0.57) | HRH3EGLN1METEPHX2 | |
| SCHEMBL1793754 | 0.85 | HRH3 (0.57) | HRH3EGLN1METEPHX2 | |
| SCHEMBL1795444 | 0.84 | HRH3 (0.68) | HRH3METEPHX2 | |
| SCHEMBL1795442 | 0.84 | HRH3 (0.68) | HRH3METEPHX2 | |
| Hydrochloric Acid SCHEMBL1797032 | 0.84 | HRH3 (0.56) | HRH3EGLN1METEPHX2 | |
| Hydrochloric Acid SCHEMBL1797028 | 0.84 | HRH3 (0.56) | HRH3EGLN1METEPHX2 | |
| SCHEMBL3278791 | 0.79 | HRH3 (0.64) | HRH3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885BRAF 3912/4885EGLN1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.